scanX
Aurobindo Pharma

Aurobindo Pharma

1,154.80
+31.00
(2.76%)
hide
Key Fundamentals
Add Ratio
Market Cap
65,270.50 Cr
EPS
59.81
PE Ratio
19.75
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,360.70
52 Week Low
1,010.00
PB Ratio
1.93
Debt to Equity
0.24
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from26 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+80.77 %
+80.77 %
Hold
Hold0.0 %
0.0 %
Sell
Sell+19.23 %
+19.23 %
Forecast For
Actual

Company News

View All News
Caret
positive
Aurobindo Pharma Targets EBITDA Breakeven at China Plant by Q3-Q4 FY'263 days ago
Aurobindo Pharma announced several financial and operational targets during a conference call. The company's China plant is targeting EBITDA breakeven by Q3-Q4 FY'26. For FY'26, Aurobindo expects EBITDA margins of 20-21% and anticipates generating over €1 billion in revenue from Europe. The company projects ongoing growth driven by multiple factors including Pen-G facility ramp-up, biosimilar portfolio launch, biologic CMO progress, injectable business enhancement, supply from China plant to Europe, new product releases, and the acquisition of Lannett in the U.S.
neutral
Aurobindo Pharma Updates on Plant Operations and Revenue Outlook4 days ago
Aurobindo Pharma announced plans to increase production at its Kakinada Pen-G plant. The company expects its China plant to reach break-even in the third or fourth quarter. Revlimid sales were low in Q2, with no sales anticipated in Q3. The pharmaceutical company indicated that no major capital expenditures are expected in the near term.
positive
Aurobindo Pharma Reports 6.3% Revenue Growth to ₹8,286 Crores in Q2FY265 days ago
Aurobindo Pharma Limited announced quarterly results with revenue from operations increasing 6.3% year-over-year to ₹8,286 crores, driven by strong performance in US, Europe and Growth Markets. EBITDA grew 7.1% to ₹1,678 crores with a margin of 20.3%. Net profit rose 3.8% to ₹848 crores. The US formulations business generated ₹3,638 crores (43.9% of total revenue), while Europe formulations contributed ₹2,480 crores with 17.8% growth. The company filed 13 ANDAs with US FDA, received 7 final approvals, and launched 6 products during the quarter. R&D spending was ₹414 crores (5% of sales). The company maintains a strong net cash position of $170 million and generated free cash flows of $57 million before dividends and buybacks. In biosimilars, three products including trastuzumab biosimilar were approved by European Commission, and four biosimilar products including bevacizumab and trastuzumab biosimilars were approved by MHRA UK.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,697.80
#1 4,05,823.50
38.84
#1 54,729.00
9.71
#1 10,980
2.89
57.82
Divis Laboratories
6,691.50
1,76,709.20
71.49
9,712.00
18.67
2,191
35.10
59.81
Cipla
1,511.50
1,21,623.50
22.50
28,409.50
7.12
5,291
3.71
42.33
Torrent Pharmaceuticals
3,817.50
1,21,163.50
60.37
11,539.40
6.99
1,911
30.46
70.23
Dr Reddys Laboratories
1,198.70
1,00,604.30
#1 17.43
33,741.20
16.73
5,725
-0.38
35.45
Zydus Life Science
948.40
94,998.60
18.95
23,511.00
18.55
4,615
34.60
35.94
Mankind Pharma
2,236.60
93,357.70
52.03
12,744.20
#1 20.90
2,007
-21.05
23.38
Lupin
1,990.20
90,062.90
20.88
22,909.50
13.74
3,306
#1 72.75
56.75
Alkem Laboratories
5,679.50
67,775.40
29.10
13,458.30
3.70
2,216
21.39
64.68
Aurobindo Pharma
1,154.80
#10 65,270.50
#3 19.75
#3 32,345.60
#7 9.43
#5 3,484
#6 3.81
61.48
Growth Rate
Revenue Growth
9.43 %
Net Income Growth
9.93 %
Cash Flow Change
61.21 %
ROE
0.47 %
ROCE
10.77 %
EBITDA Margin (Avg.)
2.86 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
3,151
3,272
3,324
3,450
3,710
3,728
3,742
3,871
3,625
3,645
4,366
4,302
4,033
4,226
4,694
5,242
5,234
5,377
5,539
5,830
6,108
5,951
6,432
9,300
6,071
5,802
5,987
6,089
5,844
6,218
5,731
6,481
6,514
6,907
7,339
7,434
7,628
7,679
7,783
8,052
8,516
7,899
8,359
Expenses
2,506
2,574
2,586
2,688
2,885
2,878
2,847
3,011
2,920
2,845
3,319
3,311
3,261
3,539
3,792
4,208
4,271
4,311
4,473
4,701
4,862
4,679
5,071
5,011
4,735
4,502
4,766
4,993
5,002
5,303
4,950
5,453
5,477
5,772
5,846
5,753
6,042
5,949
6,230
6,401
6,622
6,265
6,608
EBITDA
645
698
738
762
825
851
895
860
704
800
1,047
992
772
687
902
1,033
963
1,066
1,066
1,130
1,247
1,271
1,361
4,290
1,335
1,300
1,220
1,096
842
914
781
1,027
1,037
1,135
1,493
1,681
1,585
1,730
1,553
1,652
1,894
1,634
1,752
Operating Profit %
20 %
21 %
22 %
22 %
21 %
22 %
23 %
22 %
18 %
21 %
24 %
22 %
18 %
15 %
19 %
19 %
18 %
20 %
19 %
19 %
20 %
20 %
20 %
21 %
21 %
21 %
19 %
17 %
14 %
14 %
13 %
15 %
14 %
15 %
18 %
21 %
19 %
20 %
19 %
19 %
21 %
20 %
20 %
Depreciation
85
89
93
99
111
106
110
111
100
131
132
138
157
155
164
163
187
241
243
250
232
256
257
277
266
280
294
299
254
280
298
321
346
327
418
423
354
404
382
419
444
406
429
Interest
21
31
68
9
25
21
18
14
14
17
17
19
25
30
35
48
50
50
41
37
32
21
16
20
18
13
10
16
9
15
25
45
56
57
68
76
89
111
113
119
115
98
95
Profit Before Tax
557
634
631
717
761
786
830
796
649
709
979
902
651
571
787
917
816
863
864
938
1,078
1,084
1,193
4,005
1,061
1,018
968
794
594
679
523
680
730
812
1,076
1,262
1,230
1,324
1,208
1,200
1,335
1,207
1,276
Tax
153
162
178
173
206
201
224
218
117
191
198
307
122
116
175
205
231
228
224
233
229
301
386
1,058
260
248
271
190
18
159
113
189
224
242
324
323
323
406
391
354
432
383
428
Net Profit
403
472
453
545
555
585
606
579
532
518
781
595
529
456
611
712
585
636
640
705
849
783
807
2,948
801
770
697
604
576
520
410
491
506
570
752
940
907
918
817
846
903
824
848
EPS in ₹
13.84
16.18
7.77
9.32
9.49
9.99
10.41
9.88
9.10
8.85
13.33
10.16
9.02
7.78
10.44
12.15
9.99
10.85
10.92
12.04
14.50
13.32
13.78
50.31
13.67
13.14
11.89
10.32
9.84
8.88
6.99
8.38
8.64
9.74
12.83
16.04
15.51
15.69
14.00
14.56
15.56
14.20
14.61
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
49,785
Fixed Assets
3,706
4,180
4,834
6,521
8,475
9,397
9,374
10,532
11,024
14,493
14,794
Current Assets
8,299
10,294
9,206
12,178
15,332
16,413
19,824
18,123
21,460
23,772
27,163
Capital Work in Progress
420
848
1,458
1,583
1,669
1,986
3,062
3,747
5,390
3,869
4,900
Investments
20
123
246
312
360
555
591
997
543
372
252
Other Assets
8,770
10,769
9,712
12,686
15,951
16,991
20,828
18,645
22,934
26,338
29,839
Total Liabilities
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
49,785
Current Liabilities
6,136
7,840
6,606
8,666
12,021
11,385
10,665
8,156
11,494
12,199
14,682
Non Current Liabilities
1,596
790
270
753
541
718
1,260
1,192
1,544
3,022
2,456
Total Equity
5,182
7,290
9,374
11,682
13,892
16,825
21,929
24,574
26,852
29,851
32,647
Reserve & Surplus
5,127
7,229
9,313
11,622
13,832
16,766
21,871
24,517
26,781
29,784
32,595
Share Capital
29
59
59
59
59
59
59
59
59
59
58
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
313
340
-424
892
666
871
2,561
-1,164
230
-1,007
2,178
Investing Activities
-1,017
-1,446
-1,787
-1,927
-2,904
-1,563
597
-3,211
-3,971
-4,242
-1,866
Operating Activities
1,237
1,420
3,279
1,955
1,651
4,381
3,329
5,017
2,387
2,435
3,925
Financing Activities
93
365
-1,915
864
1,919
-1,947
-1,365
-2,969
1,814
800
120
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
51.94 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.80 %
51.82 %
51.82 %
51.82 %
51.82 %
51.82 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
18.02 %
16.73 %
16.59 %
16.29 %
15.33 %
14.37 %
14.21 %
DIIs
10.99 %
12.72 %
13.82 %
15.11 %
15.83 %
15.58 %
16.23 %
14.89 %
15.08 %
15.73 %
17.94 %
20.23 %
23.28 %
24.77 %
25.13 %
25.20 %
26.23 %
26.93 %
27.60 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.71 %
8.54 %
9.60 %
8.99 %
8.37 %
8.80 %
8.65 %
9.42 %
8.54 %
7.01 %
6.15 %
5.64 %
5.52 %
5.47 %
5.33 %
5.52 %
5.47 %
5.67 %
5.25 %
Others
28.36 %
26.91 %
24.74 %
24.07 %
23.97 %
23.79 %
23.29 %
23.85 %
24.54 %
25.42 %
24.07 %
22.29 %
1.36 %
1.23 %
1.13 %
1.17 %
1.15 %
1.20 %
1.13 %
No of Share Holders
2,32,634
2,43,315
3,29,940
3,41,568
3,38,639
3,59,684
3,58,459
3,69,828
3,43,617
2,93,214
2,59,638
2,41,944
2,44,575
2,38,622
2,48,488
2,57,962
2,69,323
2,72,208
2,47,662

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.2 2.5 2.5 3 4 9 7.5 4.5 0.00
Dividend Yield (%) 0.00 0.57 0.32 0.61 0.34 0.6 1.77 0.69 0.39 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
23 Feb 2021 DIVIDEND Dividend
₹ 1.50 /share
 22 Feb 2021 959.45 858.10
30 Aug 2021 DIVIDEND Dividend
₹ 1.50 /share
 27 Aug 2021 856.50 709.95
18 Nov 2021 DIVIDEND Dividend
₹ 1.50 /share
 17 Nov 2021 690.05 666.55
21 Feb 2022 DIVIDEND Dividend
₹ 1.50 /share
 18 Feb 2022 650.05 656.80
07 Jun 2022 DIVIDEND Dividend
₹ 4.50 /share
 06 Jun 2022 529.70 522.50
17 Feb 2023 DIVIDEND Dividend
₹ 3.00 /share
 17 Feb 2023 445.05 479.90
20 Nov 2023 DIVIDEND Dividend
₹ 3.00 /share
 20 Nov 2023 936.40 1,007.35
20 Feb 2024 DIVIDEND Dividend
₹ 1.50 /share
 20 Feb 2024 1,002.00 1,040.50
29 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Aug 2024 1,404.35 1,564.20
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 09 Nov 2024 1,396.00 1,327.55
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Feb 2025 1,156.60 1,191.75
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 26 May 2025 1,216.90 1,197.10
04 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 04 Aug 2025 1,101.40 1,079.80
08 Aug 2025 DIVIDEND Dividend
₹ 4.00 /share
 08 Aug 2025 1,079.80 1,069.60
10 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 10 Sept 2025 1,052.90 1,044.05
05 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Nov 2025 1,098.95 1,151.00

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation5 days ago
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 5 20255 days ago
Announcement under Regulation 30 (LODR)-Change in Management6 days ago
Clarification With Reference To Movement In Volume.Oct 30, 2025
Clarification sought from Aurobindo Pharma LtdOct 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On November 5 2025 For Consideration Unaudited Financial Results For The Second Quarter & Half Year Ended On September 30 2025.Oct 24, 2025
Announcement under Regulation 30 (LODR)-AcquisitionOct 23, 2025
Announcement under Regulation 30 (LODR)-AcquisitionOct 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementOct 01, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 01, 2025
Announcement under Regulation 30 (LODR)-AcquisitionSep 26, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 26, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 26, 2025
Closure of Trading WindowSep 24, 2025
Fire Accident At Unit-IV Of APL Healthcare Limited A Wholly Owned Subsidiary Of The CompanySep 19, 2025
Curateq Biologics Announces Successful Completion Of Phase 3 Clinical Study For Denosumab Biosimilar.Sep 19, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Sep 17, 2025
Clarification On Significant Volume Movement In CompanyS SharesSep 12, 2025
Clarification sought from Aurobindo Pharma LtdSep 12, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 11, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 10, 2025
Completion Of US FDA Inspection At Unit-XII Of Aurobindo Pharma LimitedSep 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 02, 2025
Completion Of US FDA Inspection At Unit-I Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The CompanyAug 29, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2025
Curateq Biologics S.R.O A Wholly Owned Step-Down Subsidiary Of The Company Receives Approval For Biosimilar Dazublys From UKS MHRAAug 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Rumour verification - Regulation 30(11)Aug 20, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 15, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 14, 2025
Notice Of 38Th Annual General Meeting Scheduled To Be Held On September 10 2025Aug 14, 2025
Reg. 34 (1) Annual Report.Aug 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Intimation Of 38Th Annual General Meeting Of Aurobindo Pharma Limited.Aug 12, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 04, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 04, 2025
Intimation Of Record Date For Payment Of Interim Dividend For The FY 2025-26Aug 04, 2025
Corporate Action-Board approves DividendAug 04, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On August 4 2025Aug 04, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Mid Cap Fund Direct-Growth
0.00%
-13344745
-1.70%
-1.65%
SBI Large & Midcap Fund Direct Plan-Growth
0.00%
-6500000
-2.07%
-1.73%
Quant Mid Cap Fund Direct-Growth
0.00%
-5969000
-7.83%
-7.38%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-4739621
-8.25%
-6.53%
ICICI Prudential India Opportunities Fund Direct - Growth
0.00%
-4374265
-1.54%
-1.28%
Quant Multi Cap Fund Direct-Growth
0.00%
-4294483
-5.04%
-4.80%
ICICI Prudential Large Cap Fund Direct-Growth
0.00%
-3278275
-0.49%
-0.47%
ICICI Prudential Value Direct-Growth
0.00%
-3230588
-0.63%
-0.62%
HDFC Balanced Advantage Fund Direct-Growth
0.00%
-2722312
-0.29%
-0.28%
Mirae Asset Large & Midcap Fund Direct-Growth
0.00%
-2709196
-0.72%
-1.00%
HDFC Large and Mid Cap Fund Direct- Growth
0.00%
-2177529
-0.88%
-0.86%
SBI Arbitrage Opportunities Fund Direct-Growth
0.00%
-2134000
-0.59%
-0.51%
Mirae Asset Large Cap Fund Direct- Growth
0.00%
-2020497
-0.55%
-0.55%
Kotak Arbitrage Fund Direct-Growth
0.00%
-1916200
-0.29%
-0.34%
ICICI Prudential Equity Arbitrage Direct-Growth
0.00%
-1896400
-0.63%
-0.59%
ICICI Prudential Equity & Debt Fund Direct-Growth
0.00%
-1868985
-0.44%
-0.43%
Nippon India Pharma Fund Direct-Growth
0.00%
-1702630
-2.27%
-2.09%
Invesco India Arbitrage Fund Direct-Growth
0.00%
-1665950
-0.67%
-0.39%
Mirae Asset Midcap Fund Direct - Growth
0.00%
-1408813
-0.89%
-1.00%
Mirae Asset ELSS Tax Saver Fund Direct-Growth
0.00%
-1328028
-0.56%
-0.85%
Bandhan Value Fund Direct-Growth
0.00%
-1295000
-1.41%
-1.35%
ICICI Prudential Innovation Fund Direct - Growth
0.00%
-1290775
-1.96%
-2.00%
Aditya Birla Sun Life Arbitrage Fund Direct-Growth
0.00%
-1254550
-0.60%
-0.48%
Nippon India Arbitrage Fund Direct-Growth
0.00%
-1181950
-0.83%
-0.70%
Tata Arbitrage Fund Direct - Growth
0.00%
-1115400
-0.63%
-0.55%

Technical Indicators

RSI(14)
Neutral
53.78
ATR(14)
Less Volatile
26.46
STOCH(9,6)
Neutral
71.72
STOCH RSI(14)
Neutral
63.43
MACD(12,26)
Bullish
2.79
ADX(14)
Weak Trend
13.83
UO(9)
Bearish
52.56
ROC(12)
Uptrend And Accelerating
2.22
WillR(14)
Neutral
-47.79
Bearish
3
Neutral
4
Bullish
2

About Aurobindo Pharma

Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has 9 R&D facilities. APL has filed numerous Drug Master Files and Abbreviated New Drug Applications in various countries. The company has expanded through acquisitions and joint ventures in multiple countries, including the UK, Italy, and Portugal. APL has also entered the biosimilars and vaccines markets. The company serves over 150 countries and is among the top 5 manufacturers of semi-synthetic penicillins globally.
Website
https://www.aurobindo.com
Chairperson NameM R Kumar
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104